Molecular Oncology

Research interest

The Molecular Oncology Laboratory is focused in the role of signal transduction pathways in cancer and the therapy of cancer. Our group works in several aspects of cell signalling, specially MAPK and the implication in chemo and radio resistance. We are currently working on new chemotherapeutic agents based on molecular alterations ( Dasatinib, Imatinib, etc) but also we are interested in the conventional chemotherapy ( cisplatin, doxorubicin , 5-Fu) and radiotherapy. In addition we are also in the role of this signalling pathways in cellular transformation mediated by Oncogenes and tumour suppressor.

The other main project is the study of E1a gene from adenovirus. On one side we are interested in the oncogenic properties of E1a in cooperation with known oncogenes such as v-H.-ras or the blockage on tumour suppressor such as p53 or pRb. But interestingly E1a is considered as potent inducer of chemo and radio sensitizer in several experimental system and our group is interested in this issue as well as the role of signalling transduction in this effect.

In addition our group is also involved in other projects related to pharmacogenomics and molecular diagnostic in collaboration with tdifferent clinical departments of CHUA (oncology, radiotherapy. Haematology)

  • 100%

Funding

    • Título: Autofagia en cáncer: implicación de MAPKS en resistencia y supresión tumoral
      Entidad financiadora: Ministerio de Economía y Competitividad
      I.P.: Ricardo Sánchez Prieto
      Duración, desde: 01/01/2013   hasta: 31/12/2015
    • Título: Papel de la señalización intracelular mediada por proteínas quinasas en los fenómenos de quimio y radio resistencia
      Entidad financiadora: Fundación Leticia Castillejo
      I.P.: Ricardo Sánchez Prieto
      Duración, desde: 01/01/2014   hasta: 29/09/2015
    • Título: Papel de la señalización intracelular mediada por proteínas quinasas en los fenómenos de quimio y radio resistencia
      Entidad financiadora: Fundación Leticia Castillejo
      I.P.: Ricardo Sánchez Prieto
      Duración, desde: 04/07/2012   hasta: 04/09/2013
    • Título: Bases moleculares de la transformación y supresión tumoral asociada a la expresión del gen E1A de adenovirus: desarrollo de modelos in vivo
      Entidad financiadora: Consejería de Educación y Ciencia, JCCM
      I.P.: Ricardo Sánchez Prieto
      Duración, desde: 01/04/2010   hasta: 31/03/2013
    • Título: Papel de la ruta de señalización P38MAPK en terapia de cáncer basada en daño genotóxico
      Entidad financiadora: Ministerio de Ciencia e Innovación
      I.P.: Ricardo Sánchez Prieto
      Duración, desde: 01/11/2009   hasta: 31/10/2012
    • Título: Papel de la señalización intracelular mediada por proteínas quinasas en los fenómenos de quimio y radio resistencia
      Entidad financiadora: Fundación Leticia Castillejo
      I.P.: Ricardo Sánchez Prieto
      Duración, desde: 01/06/2011   hasta: 30/09/2012
  • 100%

Publications

  • García-Cano J, Ambroise G, Pascual-Serra R, Carrión MC, Serrano-Oviedo L, Ortega-Muelas M, Cimas FJ, Sabater S, Ruiz-Hidalgo MJ, Sanchez Perez I, Mas A, Jalón FA, Vazquez A, Sánchez-Prieto R. Exploiting the potential of autophagy in cisplatin therapy: A new strategy to overcome resistance. Oncotarget. 2015 Jun 20;6(17):15551-65. (A).
  • Valero ML, Cimas FJ, Arias L, Melgar-Rojas P, García E, Callejas-Valera JL, Cano JG, Serrano Oviedo L, de la Cruz-Morcillo MA, Sánchez-Pérez I, Sánchez-Prieto R. E1a promotes c-Myc-dependent replicative stress: Implications in glioblastoma radiosensitization. Cell Cycle. 2014;13(1):52-61. doi: 10.4161/cc.26754. [Epub 2013]. (A).
  • de la Cruz-Morcillo MA, García-Cano J, Arias-González L, García-Gil E, Artacho-Cordón F, Ríos-Arrabal S, Valero ML, Cimas FJ, Serrano-Oviedo L, Villas MV, Romero-Fernández J, Núñez MI, Sánchez-Prieto R. Abrogation of the p38 MAPK ? signaling pathway does not promote radioresistance but its activity is required for 5-Fluorouracil-associated radiosensitivity. Cancer Lett. 2013; pii: S0304-3835(13)00096-7. doi: 10.1016/j.canlet.2013.01.050. (A).
  • Elorza A, Soro-Arnáiz I, Meléndez F, Rodríguez V, Marsboom G, de Cárcer G, Acosta B, Albacete L, Ordóñez A, Serrano-Oviedo L, Giménez JM, Vara A, Salinas A, Sánchez-Prieto R, Martín R, Sánchez F, Malumbres M, Landázuri MO, Aragonés J. HIF2? Acts as an mTORC1 Activator through the Amino Acid Carrier SLC7A5. Mol Cell. 2012. pii: S1097-2765(12)00817-9. (A).
  • Klionsky DJ, …, Sanchez-Prieto R, …, Zuckerbraun B. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012. 8[4]: 445-544. (A).
  • Giménez-Bachs JM, Salinas-Sánchez AS, Serrano-Oviedo L, Nam-Cha SH, Rubio-Del Campo A, Sánchez-Prieto R. Carbonic anhydrase IX as a specific biomarker for clear cell renal cell carcinoma: comparative study of Western blot and immunohistochemistry and implications for diagnosis. Scand J Urol Nephrol. 2012; 46(5):358-364. (A).
  • Hossain S, de la Cruz-Morcillo MA, Sanchez-Prieto R, Almazan G. Mitogen-activated protein kinase p38 regulates krox-20 to direct schwann cell differentiation and peripheral myelination. Glia. 2012. 60[7]: 1130-1144. (A).
  • de la Cruz-Morcillo MA, Sánchez-Prieto R. Autop38-phagy and apop38-tosis in genotoxic stress: A strange duo.Autophagy. 2012. 8[1]: 135-7. [Epub 2011]. (A).
  • de la Cruz-Morcillo MA, Valero ML, Callejas-Valera JL, Arias-González L, Melgar-Rojas P, Galán-Moya EM, García-Gil E, García-Cano J, Sánchez-Prieto R. P38MAPK is a major determinant of the balance between apoptosis and autophagy triggered by 5-fluorouracil: implication in resistance. Oncogene. 2012. 31[9]: 1073-1085. [Epub 2011]. (A).
  • Salinas-Sánchez AS, Giménez-Bachs JM, Serrano-Oviedo L, Nam Cha S, Sánchez-Prieto R. Role of Mitogen-Activated Protein Kinase (MAPK) in the Sporadic Renal Cell Carcinoma. Actas Urol Esp. 2012. 36[2]: 99-103. [Epub 2011]. (A).
  • Galan-Moya EM, de la Cruz-Morcillo MA, Valero ML, Callejas-Valera JL, Melgar-Rojas P, Losa JH, Salcedo M, Fernández-Aramburo A, Cajal SR, Sánchez-Prieto R. Balance between MKK6 and MKK3 Mediates p38 MAPK Associated Resistance to Cisplatin in NSCLC. PLoS One. 2011. 6[12]: e28406. (A).
  • Aceves-Luquero CI, Agarwal A, Callejas-Valera JL, Arias-González L, Esparís-Ogando A, del Peso Ovalle L, Bellón-Echeverria I, de la Cruz-Morcillo MA, Galán Moya EM, Moreno Gimeno I, Gómez JC, Deininger MW, Pandiella A, Sánchez Prieto R. ERK2, but not ERK1, mediates acquired and ‘de novo’ resistance to imatinib mesylate: implication for CML therapy. PLoS One. 2009. 4[7]: 604-607. (A).
  • Galan-Moya EM, Hernandez-Losa J, Aceves Luquero CI, de la Cruz-Morcillo MA, Ramirez-Castillejo C, Callejas-Valera JL, Arriaga A, Aranburo AF, Cajal SR, Silvio Gutkind J, Sanchez-Prieto R. c-Abl activates p38 MAPK independently of its tyrosine kinase activity: Implications in cisplatin-based therapy. Int J Cancer. 2008. 122[2]: 289-297. (A).
  • Callejas-Valera JL, Guinea-Viniegra J, Ramírez-Castillejo C, Recio JA, Galan-Moya EM, Martinez N, Rojas JM, Ramón Y Cajal S, Sánchez-Prieto R. E1A gene expression blocks the ERK1/2 signaling pathway by promoting nuclear localization and MKPS up-regulation: Implication in V-H-ras induced senescence. J Biol Chem. 2008. 283[9]: 13450-13458. (A).
  • Romero J, Zapata I, Córdoba S, Jimeno JM, López-Martín JA, Tercero JC, De La Torre A, Vargas JA, Molerón R, Sánchez-Prieto R. In vitro radiosensitisation by trabectedin in human cancer cell lines. Eur J Cancer. 2008. 44[12]: 1726-1733. (A).
  • Pascual A, Pariente M, Godinez JM, Sanchez-Prieto R, Atienzar M, Segura M, Poblet E.. High prevalence of human papillomavirus 16 in penile carcinoma. Histol Histopathol. 2007. 22[2]: 177-183. (A).
  • Fernandez-Soria V, Lleonart ME, Diaz-Fuertes M, Villuendas R, Sanchez-Prieto R, Fabra A, Ramon y Cajal S. Adenovirus E1A orchestrates the urokinase-plasminogen activator system and upregulates PAI-2 expression, supporting a tumor suppressor effect. Int J Oncol. 2006. 28[1]: 143-148. (A).
  • Guinea J, Martínez N, Aceves CI, Galán E, de la Cruz MA, Callejas JL, Arraiga A, Ramírez C, Villas MV, Rojas JM, Sánchez-Prieto R. PKB/Akt media la radio sensibilidad asociada a Ataxia Telangiectasia. Oncología. 2005. 28: 329-337. (A).
  • Poblet E, Jimenez F, de Cabo C, Prieto-Martin A, Sanchez-Prieto R. The calcium-binding protein calretinin is a marker of the companion cell layer of the human hair follicle. Br J Dermatol. 2005. 152[6]: 1316-1320. (A).
  • Viniegra JG, Martinez N, Modirassari P, Losa JH, Parada CC, Lobo VJ, Luquero CI, Alvarez-Vallina L, Cajal S, Rojas JM, Sanchez-Prieto R. Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM. J Biol Chem. 2005. 280[6]: 4029-4036. [Epub 2004]. (A).
  • Sanchez-Arevalo Lobo VJ, Aceves Luquero CI, Alvarez-Vallina L, Tipping AJ, Viniegra JG, Hernandez Losa J, Parada Cobo C, Galan Moya EM, Gayoso Cruz J, Melo JV, Ramon y Cajal S, Sanchez-Prieto R. Modulation of the p38 MAPK pathway through Bcr/Abl: Implications in the cellular response to Ara-C. Biochem J. 2005. 387[1]: 231-238. (A).

Ricardo Sánchez Prieto

Director

People

Permanent staff
PhD students
Students

Phone: (+34) 967 599 200

Contact information

Facultad de Medicina de Albacete

Universidad de Castilla-La Mancha

C/ Almansa, 14.

02008 Albacete (España)

telefono (-34) 967 599 200, Ext. 2987

fax (+34) 967 599 327

  • 100%